The Mutated in Colorectal Cancer gene (MCC) was identified as a tumor suppressor that is deleted in sporadic and familial colorectal cancers. MCC is located at chromosome region 5q21. This region is often deleted in and associated with adenomas and carcinomas. Allele losses in the regions contiguous to MCC correlate with a high rate of colorectal tumors. MCC has been reported to be widely expressed and most abundant in epithelial cells and brain. It is a protein of 829 amino acids with a short sequence homologous to the m3 muscarinic acetylcholine receptor. Immunolocalization studies show MCC in the lateral plasma membrane of intestinal epithelial cells. In brain, MCC is abundant in the molecular layer of the cerebellum and is associated with various organelles, such as the plasma membrane. Although overexpression of wild type MCC protein blocks progression through the cell cycle, a mutated MCC, that contains a Gln instead of Arg-506, does not. Therefore, wild type MCC functions as a negative regulator of the cell cycle. Mutations or deletions in MCC might interfere with its physiological role and allow unrestricted cell proliferation (i.e. tumor formation).
This antibody is routinely tested by western blot analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.